Lincoln National Corp Lineage Cell Therapeutics, Inc. Transaction History

Lincoln National Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	BUY	$1.2 - $1.53 $630 - $803	525 Added 0.34%	156,225 $234,000
Q4 2022 Feb 07, 2023	SELL	$1.02 - $1.5 $63,240 - $93,000	-62,000 Reduced 28.48%	155,700 $182,000
Q3 2022 Nov 03, 2022	SELL	$1.13 - $1.77 $38,194 - $59,826	-33,800 Reduced 13.44%	217,700 $246,000
Q2 2022 Aug 02, 2022	BUY	$1.12 - $1.61 $65,632 - $94,346	58,600 Added 30.38%	251,500 $397,000
Q1 2022 May 09, 2022	SELL	$1.21 - $2.48 $726 - $1,488	-600 Reduced 0.31%	192,900 $297,000
Q4 2021 Jan 26, 2022	BUY	$1.84 - $2.68 $71,576 - $104,252	38,900 Added 25.16%	193,500 $474,000
Q3 2021 Nov 05, 2021	BUY	$2.26 - $2.86 $349,395 - $442,156	154,600 New	154,600 $390,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $91.7M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.